Gastroenterologia.net
OncologiaMedica.net
Neurologia
OncoGinecologia.net

OncologyOnline.net

Oncology Xagena

A phase II trial of Everolimus plus Octreotide LAR as first-line treatment for patients with previously untreated, well-differentiated gastroenteropancreatic NETs and NETs of lung origin, both functio ...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the gut ( the microbiome ) and response to immunotherapy. In the study, the ability o ...


Indoleamine 2,3-dioxygenase-1 ( IDO1 ) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveilla ...


Sedation is used to an increasing extent in end-of-life care. Definitions and indications in this field are based on expert opinions and case series. Little is known about this practice at palliativ ...


The idea that a non-Platinum therapy might artificially extend the Platinum-free interval, thereby improving outcomes in ovarian cancer patients who experience recurrence between 6 and 12 months after ...


Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...


Immune checkpoint inhibitors rely on the presence of ongoing immune response to exert their antitumor effect. Little is known whether an age-related decline in immune function negatively influences ...


With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The American Journal of Pathology, resea ...


New patient-reported quality-of-life data from an exploratory endpoint in the pivotal phase 3 CheckMate -141 trial evaluating Nivolumab ( Opdivo ) in patients with recurrent or metastatic squamous cel ...


A treatment harnesses the immune system to shrink tumors in bladder cancer patients that cannot take the most effective chemotherapy. These are the findings of a clinical trial led by researchers at ...


Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...


Nivolumab ( Opdivo ) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Cong ...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...


A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing cells with increased MET gene copy ...


The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...